These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1228 related articles for article (PubMed ID: 23427891)

  • 1. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.
    Hotchkiss RS; Monneret G; Payen D
    Lancet Infect Dis; 2013 Mar; 13(3):260-8. PubMed ID: 23427891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
    Chang KC; Burnham CA; Compton SM; Rasche DP; Mazuski RJ; McDonough JS; Unsinger J; Korman AJ; Green JM; Hotchkiss RS
    Crit Care; 2013 May; 17(3):R85. PubMed ID: 23663657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
    Patil NK; Bohannon JK; Sherwood ER
    Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advances in sepsis induced immunosuppression and immunomodulation therapy].
    He X; Bo L; Jiang C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Dec; 30(12):1202-1205. PubMed ID: 30592959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new normal: immunomodulatory agents against sepsis immune suppression.
    Hutchins NA; Unsinger J; Hotchkiss RS; Ayala A
    Trends Mol Med; 2014 Apr; 20(4):224-33. PubMed ID: 24485901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.
    Shindo Y; Unsinger J; Burnham CA; Green JM; Hotchkiss RS
    Shock; 2015 Apr; 43(4):334-43. PubMed ID: 25565644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?
    Boomer JS; Green JM; Hotchkiss RS
    Virulence; 2014 Jan; 5(1):45-56. PubMed ID: 24067565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Sepsis-Induced Immunosuppression.
    Venet F; Rimmelé T; Monneret G
    Crit Care Clin; 2018 Jan; 34(1):97-106. PubMed ID: 29149944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunomodulation for sepsis: a change of tack?].
    Leentjens J; Kox M; Pickkers P
    Ned Tijdschr Geneeskd; 2014; 158():A6859. PubMed ID: 24518844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of sepsis-induced immunosuppression and immunological modification therapies for sepsis.
    Ono S; Tsujimoto H; Hiraki S; Aosasa S
    Ann Gastroenterol Surg; 2018 Sep; 2(5):351-358. PubMed ID: 30238076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options.
    Hamers L; Kox M; Pickkers P
    Minerva Anestesiol; 2015 Apr; 81(4):426-39. PubMed ID: 24878876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
    Patera AC; Drewry AM; Chang K; Beiter ER; Osborne D; Hotchkiss RS
    J Leukoc Biol; 2016 Dec; 100(6):1239-1254. PubMed ID: 27671246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis.
    Brahmamdam P; Inoue S; Unsinger J; Chang KC; McDunn JE; Hotchkiss RS
    J Leukoc Biol; 2010 Aug; 88(2):233-40. PubMed ID: 20483923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-tyrosine modulates the immune response induced by bacterial endotoxins.
    Montagna DR; Duarte A; Todero MF; Ruggiero RA; Isturiz M; Rearte B
    Immunobiology; 2020 Jan; 225(1):151856. PubMed ID: 31744627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 signaling pathway in sepsis: Does it have a future?
    Chen R; Zhou L
    Clin Immunol; 2021 Aug; 229():108742. PubMed ID: 33905818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the understanding and treatment of sepsis-induced immunosuppression.
    Venet F; Monneret G
    Nat Rev Nephrol; 2018 Feb; 14(2):121-137. PubMed ID: 29225343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effect of human ghrelin and growth hormone: Attenuation of immunosuppression in septic aged rats.
    Zhou M; Yang WL; Aziz M; Ma G; Wang P
    Biochim Biophys Acta Mol Basis Dis; 2017 Oct; 1863(10 Pt B):2584-2593. PubMed ID: 28115288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.
    Hotchkiss RS; Monneret G; Payen D
    Nat Rev Immunol; 2013 Dec; 13(12):862-74. PubMed ID: 24232462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
    Meisel C; Schefold JC; Pschowski R; Baumann T; Hetzger K; Gregor J; Weber-Carstens S; Hasper D; Keh D; Zuckermann H; Reinke P; Volk HD
    Am J Respir Crit Care Med; 2009 Oct; 180(7):640-8. PubMed ID: 19590022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.